Skip to main content
. Author manuscript; available in PMC: 2019 Jul 15.
Published in final edited form as: Int J Radiat Oncol Biol Phys. 2018 Mar 14;101(4):860–874. doi: 10.1016/j.ijrobp.2018.03.002

Table 4:

Major radiotherapy advancements in Ewing Sarcoma

  • The addition of ifosfamide and etoposide (IE) to vincristine, doxorubicin and cyclophosphamide (VDC) improved both local control and overall survival while interval compression of VDC alternating with IE chemotherapy improved survival.

  • In AEWS1031, a provision for response-adapted post-operative RT as a method to reduce RT volumes for favorable responders was included to reduce risk of musculoskeletal complications after treatment.

  • Identification of older age (>18 years) and pelvic primary site as predictors of inferior local control for patients treated primarily with radiotherapy.

  • The current metastatic COG Ewing trial, AEWS1221, allows SBRT to metastatic lesions given in 5 fractions, as opposed to the current standard of 31 fractions.